Lilly and eva pharma collaborate to expand access to baricitinib in low- to middle-income countries

Lilly will license certain baricitinib manufacturing know-how to enable eva pharma to manufacture and supply treatment for various immunological diseases across 49 low- to middle-income countries in africa indianapolis and cairo , sept. 4, 2024 /prnewswire/ -- eli lilly and company (nyse: lly) and  eva pharma  announced today that the companies have entered into an agreement to expand access to baricitinib to an estimated 20,000 people in 49 low- to middle-income countries in africa by 2030.
EVA Ratings Summary
EVA Quant Ranking